Evidence map›Paper›PMID 38645467›Full record

ArticleAsian journal of pharmaceutical sciences2024

Shengnan Huang, Chenyang Zhou, Chengzhi Song, Xiali Zhu, Mingsan Miao, Chunming Li, Shaofeng Duan, Yurong Hu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Shengnan HuangAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.
Chenyang ZhouSchool of Pharmaceutical Sciences, Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou 450001, China.
Chengzhi SongCenter for Quantitative Biology, Peking University, Beijing 100871, China.
Xiali ZhuSchool of Pharmaceutical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.
Mingsan MiaoAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.
Chunming LiDepartment of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China.
Shaofeng DuanSchool of Pharmaceutical Sciences, Henan University, Zhengzhou 450046, China.
Yurong HuSchool of Pharmaceutical Sciences, Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou 450001, China.
Zhengzhou University · CNFirst Affiliated Hospital of Henan University · CNChongqing University · CNHenan University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postoperative tumor recurrence remains a predominant cause of treatment failure. In this study, we developed an

Indexed as

ImmunotherapyIn situ hydrogelManganese (II)Nitric oxidePost-surgical tumor recurrenceTumor microenvironment

Identifiers

PMID38645467
PMCPMC11031726
OpenAlexW4392504864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.